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Cough during the perioperative period is usually tran-sient and self-limiting. On emergence from anesthe-sia, cough may protect against aspiration. However, 
cough can also result in perioperative morbidity, includ-
ing tachyarrhythmia, arterial hypertension, cardiovascular 
collapse, and airway complications,1–9 and it may increase 
intracranial, intraabdominal, and intraocular pressure.10 An 
effective technique for preventing cough would be desirable 
in many situations where patients are at a particular risk. 
Cough-preventing strategies have been proposed, such as 
“deep extubation,”11,12 gargling with various substances,13 
or topical or intracuff lidocaine.14
The clinical relevance of intravenous (IV) lidocaine as a 
way to blunt cough during tracheal intubation is deserved 
by specific and challenging clinical circumstances where 
avoidance of neuromuscular blocking agents is recom-
mended or even mandatory. These conditions could include, 
for instance, awake intubation for expected difficult airway 
management, airway obstruction in children, known severe 
allergy to neuromuscular blocking agents, or certain neuro-
muscular disorders (eg, myasthenia gravis).15,16
The efficacy of a single IV bolus of lidocaine for the pre-
vention of cough in the perioperative period has been the 
subject of numerous randomized controlled trials (RCTs). 
Two systematic reviews have described the efficacy of IV 
lidocaine for the prevention of fentanyl-induced cough.17,18
It remains unclear though whether IV lidocaine is equally 
effective for the prevention of mechanically induced cough 
(eg, during tracheal intubation) as for the prevention of 
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KEY POINTS
• Question: Does intravenous lidocaine prevent cough? Is there a dose-responsiveness and any 
risk of harm?
• Findings: Twenty-five trials and 3507 patients were included. Within a range of 0.5–2 mg·kg−1, 
intravenous lidocaine dose dependently prevents intubation-, extubation-, and opioid-induced 
cough in adults and children. Adverse effect reporting was sparse. The risk of harm in high-
risk patients remains unknown.
• Meaning: Intravenous lidocaine dose dependently prevents perioperative cough in adults and 
children. Further research on high-risk patients is warranted.
Copyright © 2018 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
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opioid-induced cough, whether it is effective in both adults 
and children, whether there is dose responsiveness, and 
what the adverse effect profile is. We set out to address these 
issues with a systematic review and meta-analysis of RCTs.
METHODS
We followed the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines for the 
reporting of meta-analyses of RCTs.19 A complete PRISMA 
2009 checklist is provided in Supplemental Digital Content, 
Table 1, http://links.lww.com/AA/C531. A protocol of this 
systematic review has not been published but is available 
from the authors.
Search Strategy
Searches in PubMed, Embase, and Cochrane Central Register 
of Controlled Trials were performed independently by 2 
authors (S.C., A.P.) to January 1, 2017 (PubMed search strategy; 
Supplemental Digital Content, Methods 1, http://links.lww.
com/AA/C531). We selected RCTs comparing IV lidocaine 
with placebo or no treatment for the prevention of mechani-
cally or pharmacologically induced cough in adults or children 
in the perioperative setting. We also searched reference lists of 
retrieved articles. We applied no language restriction. Authors 
of original studies were contacted when reported data were 
unclear. Data from conference proceedings and abstracts were 
not considered if they were not published as full articles.
Data Extraction and Quality Assessment
One author (S.C.) extracted relevant information from each 
selected study. These data were checked by a second author 
(A.P.). Disagreement was resolved by consensus with the 
third author (M.R.T.). We specifically extracted information 
on lidocaine regimens, time point of administration, and eti-
ology of the cough (eg, at emergence of general anesthesia). 
We extracted dichotomous data on the incidence of cough 
with and without lidocaine. When relevant efficacy data 
were displayed in graphical format only, and the authors of 
the original studies did not respond to our queries, we were 
using Plot Digitizer (http://plotdigitizer.sourceforge.net), a 
freely accessible Java program, to digitize scanned plots and 
extract dichotomous data. We also extracted any informa-
tion on potential lidocaine-related adverse events.
Two investigators (S.C., A.P.) independently evaluated 
the quality of data reporting of the included studies using a 
modified Oxford score.20 That score considers the reporting 
and adequacy of randomization, allocation concealment, 
blinding, and description of dropouts, and it ranges from 
1 to 7 points for an RCT, with higher scores indicating bet-
ter quality. We regarded a score of 6–7 as high quality, 4–5 
as moderate quality, and 1–3 as low quality. Discrepancies 
and disagreement were solved by consensus with the third 
author (M.R.T.).
Statistical Analysis
The primary outcome was the incidence of cough in adults 
or children. Individual trial and summary results were 
reported as relative risk (RR) with 95% confidence inter-
val (CI). A P value ≤.05 was considered statistically signifi-
cant. An inverse variance random-effects model was used. 
Statistical heterogeneity was assessed using Higgins I2 test 
and Cochran Q test. Data from each trial were considered 
as per the intention-to-treat principle. We also computed 
numbers needed to treat (NNT) with 95% CI. Pooling data 
from all trials seemed inappropriate due to different popu-
lations (adults or children), cough etiologies, and lidocaine 
regimens. We, therefore, performed analyses stratified 
by cough etiologies (eg, at intubation, at extubation, and 
after opioid administration) and lidocaine regimens. Data 
from adults and children were examined separately. χ2 test 
was used to test for group differences (between cough eti-
ologies and lidocaine regimens), with a P value ≤.05 con-
sidered statistically significant. In adults, we performed 
meta-regression analyses to evaluate the effect of lidocaine 
dose on the incidence of cough. We assessed publication 
bias in the  adult population using 4 methods: funnel plot, 
Begg and Mazumdar test,21 Egger test,22 and trim-and-fill 
analysis. Meta-analyses were performed using Review 
Manager (RevMan [Computer program], Version 5.3; The 
Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, Denmark, 2014).
RESULTS
Characteristics of Included Studies
A total of 1603 citations were examined. After exclusions 
of 1083 nonpertinent studies, 51 studies were retrieved 
as complete articles. Of these articles, 26 were excluded 
because they did not meet inclusion criteria (Figure 1 and 
Supplemental Digital Content, Results 1, http://links.
lww.com/AA/C531). Finally, 25 RCTs (3507 patients) were 
Figure 1. Flow diagram of retrieved, excluded, and 
eventually analyzed studies.
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included (Table and Supplemental Digital Content, Table 
2, http://links.lww.com/AA/C531).23–48 In 10 trials, lido-
caine was tested for the prevention of cough at extuba-
tion,28,29,31,33,37,38,41,42,44,48 in 7 for the prevention of cough at 
intubation,23,25,26,43,45–47 and in 8 for the prevention of cough 
after opioid administration.24,27,30,34–36,39,40
Twenty trials were performed in adults (3062 patients) 
and 5 in children (445 patients).23,26,27,42,45 In 22 trials, patients 
were classified as American Society of Anesthesiologists 
(ASA) I or II; 3 trials (99 patients) included also ASA III 
patients.29,33,38 All trials compared lidocaine with placebo, 
except 1 that had a no treatment control group.29 Twenty-
three trials administered saline 0.9% as a placebo; 2 stud-
ies28,40 did not specify the nature of the placebo.
Lidocaine regimens were 0.5 mg·kg−1 IV in 6 tri-
als,24,27,34,40,46,47 1 mg·kg−1 IV in 13,25,27,28,30,31,33,35,37,40,41,44,46,
47 1.5 mg·kg−1 IV in 10,29,31,39,40,42–44,46–48 and 2 mg·kg−1 IV in 
7.23,26,36,38,45–47 In 6 trials,27,31,40,44,46,47 >1 lidocaine regimen was 
tested against placebo. In 1 trial,25 outcome data had to be 
extracted using the Plot Digitizer.
The trials were published between 1985 and 2013. The 
number of patients per trial ranged from 19 to 502 (median, 
80). Five trials came from India, 4 from Japan, 3 each from 
the United States and South Korea, 2 from Iran, and 1 each 
from the United Kingdom, Lebanon, Kosovo, Mexico, 
Spain, Taiwan, Turkey, and Israel. Twenty-three trials were 
published in English and 2 in Spanish.34,44
The median quality score of the studies was 5 (interquartile 
range, 5–6). Seven trials28,30,31,39–41,48 were of high quality and 18 
of moderate quality. None was of low quality (Supplemental 
Digital Content, Table 3, http://links.lww.com/AA/C531).
Efficacy With Different Cough Etiologies
The effect of lidocaine on cough at intubation, at extuba-
tion, and after opioid administration was assessed indepen-
dently of the lidocaine regimen.
In 4 adult trials (551 patients) and 3 pediatric trials (185 
patients), an IV lidocaine bolus was tested as a cough suppres-
sant at induction of anesthesia. All patients were intubated 
without a neuromuscular blocking agent. Lidocaine reduced 
Table. Characteristics of Included Trials
Trial Population
Lidocaine 
Dosage,  
mg·kg−1
Lidocaine 
Administration  
Time Point
Cough  
Stimulus
Cough 
Assessment 
Time Point Type of Surgery
ASA 
Class
Sample  
Size
Aouad et al23 Pediatric 2 Before intubation Intubation Intubation Adenotonsillectomy I; II 90
Bang et al 24 Adult 0.5 Before opioids Opioids Induction Elective I; II 158
Davidson and 
Gillespie25
Adult 1 Before intubation Intubation Intubation Gynecological I; II 60
Drenger and Pe’er26 Pediatric 2 Before intubation Intubation Intubation Minor ocular I; II 35
Gecaj-Gashi et al27 Pediatric 0.5; 1 Before opioids Opioids Induction Elective I; II 186
George et al28 Adult 1 Conclusion surgery Extubation Extubation Elective craniotomy I; II 76
Gonzalez et al29 Adult 1.5 Conclusion surgery Extubation Extubation Elective general, 
orthopedic, urologic, 
plastic, vascular
I; II; III 50
Guler et al30 Adult 1 Before opioids Opioids Induction Elective I; II 200
Honarmand and 
Safavi31
Adult 1; 1.5 Before intubation Extubation Extubation Abdominal, gynecological, 
and orthopedic
I; II 90
Khan et al33 Adult 1 Conclusion surgery Extubation Extubation Gynecological and 
orthopedic
II; III 30
Kim et al34 Adult 0.5 Before opioids Opioids Induction Elective I; II 500
Lim et al35 Adult 1 Before opioids Opioids Induction Elective I; II 150
Lin et al36 Adult 2 Before opioids Opioids Induction Elective I; II 60
Mikawa et al37 Adult 1 Conclusion surgery Extubation Extubation Minor gynecological and 
urological
I 50
Otero et al38 Adult 2 Conclusion surgery Extubation Extubation Supratentorial 
neurosurgery
I; II; III 19
Pandey et al39 Adult 1.5 Before opioids Opioids Induction Elective I; II 502
Pandey et al40 Adult 0.5; 1; 1.5 Before opioids Opioids Induction Elective I; II 320
Saghaei et al41 Adult 1 Conclusion surgery Extubation Extubation Cataract I; II 186
Sanikop and Bhat42 Pediatric 1.5 Conclusion surgery Extubation Extubation Cleft palate I; II 74
Stoneham et al43 Adult 1.5 Before LM insertion Intubation Intubation Elective day-hospital I; II 75
Takekawa et al44 Adult 1; 1.5 Before intubation Extubation Extubation Abdominal, gynecological, 
urological, and 
orthopedic
I; II 80
Warner et al45 Pediatric 2 Before intubation Intubation Intubation Strabismus I; II 60
Yukioka et al46 Adult 0.5; 1; 1.5; 2 Before intubation Intubation Intubation General, gynecological, 
urological, and 
orthopedic
I 208
Yukioka et al47 Adult 0.5; 1; 1.5; 2 Before intubation Intubation Intubation General, gynecological, 
urological, and 
orthopedic
I; II 208
Zamora Lozano  
et al48
Adult 1.5 Before intubation Extubation Extubation Elective I; II 40
Abbreviations: ASA, American Society of Anesthesiologists; LM, laryngeal mask.
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the incidence of cough at intubation; for adults, RR was 0.48 
(95% CI, 0.40–0.59), P < .001, P for heterogeneity = .62, I2 = 0%, 
and NNT was 4 (95% CI, 2.8–5.6) (Figure 2A); for children, 
RR was 0.44 (95% CI, 0.21–0.94), P = .04, P for heterogeneity 
= 0.36, I2 = 1%, and NNT was 7 (95% CI, 3.8–19.2) (Figure 2B).
Nine adult trials (621 patients) and 1 pediatric trial (74 
patients) tested the efficacy of an IV lidocaine bolus on 
cough at extubation. In 7 of those trials, the lidocaine bolus 
was administered briefly before extubation, and in 3 trials, 
the lidocaine bolus was administered at induction, on aver-
age 121 minutes before extubation.27,40,44 Lidocaine reduced 
the incidence of cough at extubation; for adults, RR was 
0.61 (95% CI, 0.50–0.75), P < .001, P for heterogeneity = .22, 
I2 = 25%, and NNT was 5 (95% CI, 3.4–7.2) (Figure 2A); for 
children, RR was 0.44 (95% CI, 0.28–0.70), P = .0005, and 
NNT was 4 (95% CI, 2.2–11.8) (Figure 2B).
Seven adult trials (1890 patients) and 1 pediatric trial 
(186 patients) tested the efficacy of an IV lidocaine bolus 
on cough induced by the administration of an opioid (fen-
tanyl27,30,36,39,40 or remifentanil24,34,35). Lidocaine reduced the 
incidence of opioid-induced cough; for adults, RR was 0.48 
(95% CI, 0.37–0.62), P < .001, P for heterogeneity = .11, I2 = 
42%, and NNT was 7 (95% CI, 5.1–8.2) (Figure 2A); for chil-
dren, RR was 0.29 (95% CI, 0.10–0.79), P = .02, and NNT was 
5 (95% CI, 2.8–13.4) (Figure 2B).
Dose Responsiveness
We tested for dose responsiveness using data from adult 
trials only because the number of pediatric data was too 
limited. Combined data from all 3 settings were used 
(induction-, extubation-, and opioid-induced cough).
With lidocaine 0.5 mg·kg−1 (5 trials, 898 patients), RR was 
0.66 (95% CI, 0.50–0.88) and NNT was 8 (95% CI, 5.4–14.3). 
With 1 mg·kg−1 (12 trials, 1112 patients), RR was 0.58 (95% 
CI, 0.49–0.69) and NNT was 7 (95% CI, 4.6–8.9). With 1.5 
mg·kg−1 (9 trials, 1027 patients), RR was 0.44 (95% CI, 0.33–
0.58) and NNT was 5 (95% CI, 3.3–5.2). With 2 mg·kg−1 (4 tri-
als, 375 patients), RR was 0.39 (95% CI, 0.24–0.62) and NNT 
was 3 (95% CI, 2.0–3.4) (Figure 3). Meta-regression revealed 
a significant correlation between the dose of lidocaine and 
the incidence of cough (P = .014) (Supplemental Digital 
Content, Results 2, http://links.lww.com/AA/C531). 
Moreover, meta-regression suggested dose responsiveness 
when lidocaine was used at intubation and after opioid 
administration but not at extubation (Supplemental Digital 
Content, Results 2, http://links.lww.com/AA/C531).
Publication Bias
We were checking for publication bias with data of adult 
trials only because the number of pediatric data was too 
limited. When pooling data from all adult trials, the funnel 
Figure 2. Impact of prophylactic intravenous lidocaine on cough incidence in different perioperative settings in adults (A) and children (B). Any 
lidocaine dose was included. Differences in group sizes are due to the inclusion of trials with multiple arms testing more than 1 lidocaine 
dose. CI indicates confidence interval; IV, inverse variance; Random, random-effects model.
Copyright © 2018 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
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plot showed asymmetry but with a minor effect on the effect 
estimate as indicated by the trim and fill. However, neither 
Begg and Mazumdar (P = .12) nor Egger regression asym-
metry test (P = .10) confirmed the presence of significant 
publication bias (Supplemental Digital Content, Results 3, 
http://links.lww.com/AA/C531).
Adverse Effects
In 1 study including ASA I and II patients41 and in 1 that 
included also ASA III patients,29 a delayed recovery of 
consciousness after anesthesia was reported in some 
adult patients who had received lidocaine. Both studies 
failed to systematically report adverse events. In 1 trial 
including ASA I and II patients, 1 adult patient had “tin-
nitus” after the injection of lidocaine.25 Ten studies (1160 
patients) reported on the absence of adverse effects with 
lidocaine.28,30,31,34,36,37,39,45–47 Two of those also included ASA 
III patients.33,38 The remaining studies did not report on the 
presence or absence of adverse effects.
DISCUSSION
The main finding of this meta-analysis is that IV lidocaine, 
in a dose-dependent manner between 0.5 and 2.0 mg·kg−1, 
may help in preventing cough at intubation, at extubation, 
and before opioid administration.
Cough in the perioperative setting is more often a nui-
sance than a real medical problem. Although cough is a 
protective mechanism, there are circumstances where sur-
gical patients are vulnerable and susceptible to coughing 
and bucking. For instance, cough may trigger an abrupt 
increase in intracavity, intraocular, or intracranial pressure; 
may lead to arterial and venous hypertension, tachycardia, 
arrhythmia, and cardiovascular collapse; and may induce 
bronchospasm, laryngospasm, and other airway compli-
cations, for instance, in asthmatic patients. Also, coughing 
is a well-known adverse effect of opioid administration. 
Pharmacologically induced cough may be severe enough to 
result in morbidity.49,50 In these patients, efficacious preven-
tion of cough may be warranted. However, before routine 
administration of lidocaine for the suppression of cough can 
be advocated, the benefit and potential for harm must be 
carefully weighed. The underlying mechanisms of cough 
suppression with lidocaine are not clearly understood. 
Among the mechanisms that have been proposed are sup-
pression of the excitation of airway sensory C fibers,51 selec-
tive depression of pain transmission in the spinal cord,52 
and reduction in tonic neural discharge of active peripheral 
nerve fibers.53
It also remains unclear whether the time point of lidocaine 
administration is important. In 3 studies, the lidocaine bolus 
was given before intubation, although the cough-suppressing 
effect was tested at extubation or postoperatively only.31,44,48 
All 3 trials showed a significant cough-suppressing effect 
with lidocaine. The half-time of IV lidocaine is approximately 
2 hours.54,55 This may explain why a cough-suppressing effect 
may last until the end of a short surgical procedure. It has 
also been suggested that the cough pathway is sensitized in a 
way similar to pain. Thus, the strong stimulation of laryngos-
copy or of moving a tube intratracheally may excite sensory 
C fibers and produce secondary neuroplasticity accompanied 
by cough. Lidocaine may reduce released neuropeptides and 
secondary neural change.44
We were able to test for dose responsiveness comparing 
the efficacy of 4 IV regimens: 0.5, 1.0, 1.5, and 2.0 mg·kg−1. 
To limit confounding and because the number of pediatric 
data was limited, we included data from adults only. Meta-
regression suggested dose responsiveness. With the highest 
dose, 2 mg·kg−1, 1 in 3 patients will not cough who would 
have done so had they not received lidocaine. With 0.5 
mg·kg−1, the NNT was 8.
This begs the question as to the toxicity of IV lidocaine 
and whether there is dose responsiveness for harm too. In 
2 studies, some patients from the lidocaine group regained 
consciousness later than the control patients, although seda-
tion was not searched for systematically.24,37 Many studies did 
not report on the presence or absence of adverse effects. We 
do not know whether no adverse effects occurred or whether 
they did but were not reported. Also, trials that included 
some adult ASA III patients did not specify whether adverse 
effects happened primarily in high-risk patients. IV lido-
caine is frequently used for the treatment of cardiac arrhyth-
mia,56 for systemic analgesia,57 for the prevention of pain on 
Figure 3. Impact of different pro-
phylactic intravenous lidocaine 
doses on cough incidence in 
adults. Any lidocaine dose was 
included. Differences in group 
sizes are due to the inclusion of 
trials with multiple arms testing 
more than 1 lidocaine dose. CI 
indicates confidence interval; 
IV, inverse variance; Random, 
random-effects model.
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injection of propofol,58 and for blunting deleterious hemo-
dynamic effects during laryngoscopy and extubation.45,59–61 
Recommended IV regimens for these indications range from 
1 to 2 mg·kg−1, and within this range, no major adverse effects 
have been reported.61–63 Even higher doses result in plasma 
concentrations of about 2 µg·mL−1 that are still below toxic 
levels.64,65 For the treatment of chronic pain, IV regimens 
up to 5 mg·kg−1 have been recommended.66,67
Seven trials, 3 in adults and 4 in children, that tested the 
cough-suppressing efficacy of lidocaine at induction used 
an intubation technique without muscle relaxants. The rou-
tine use of such a technique is of questionable value given 
that intubation without muscle relaxants may increase mor-
bidity of the upper airway.68
We performed various subgroup analyses to test for the 
robustness of the results. The only factor that was shown to 
have an impact on efficacy was the dose. We were unable to 
show a difference in efficacy between adults and children or 
among different cough-inducing settings.
This meta-analysis has some limitations, most of which are 
related to weaknesses of the original trials. First, and perhaps 
most important, all studies were monocentric, and most were 
of small size. Second, pooling together different trials with 
different settings or lidocaine dosages improves power and 
applicability of the analyses but may overestimate treatment 
effects in subpopulations. Third, adverse effect reporting was 
poor. Also, lidocaine has not been tested in high-risk popula-
tions, for instance, patients with arrhythmia or patients under-
going cardiac surgery or interventional cardiac procedures. 
Fourth, most trials reported only the incidence of cough; in 
this context, decreasing intensity may be as important as 
decreasing the incidence. Finally, we concentrated on preven-
tion of cough. It may be of clinical relevance to know the effi-
cacy of IV lidocaine for the treatment of established cough.
CONCLUSIONS
A single IV bolus of lidocaine may help prevent cough at 
intubation, at extubation, and after opioid administration 
in adults and children. In adults, there is evidence of dose 
responsiveness between 0.5 and 2.0 mg·kg−1; the NNT for 
the prevention of cough with the most efficacious regimen 
tested, 2 mg·kg−1, is 3. In low-risk patients (ASA I or II), 
within the tested dose range, no significant adverse events 
were reported. The risk of adverse effects and harm in high-
risk patients remains unknown. E
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